Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst

Aldeyra ’s Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a procedural PDUFA extension. Click to read.

You will be redirected in 10 seconds.